| 摘要 |
<p>The use of an anti-inflammatory bowel disease quinoline-3-carboxamide compound comprising structure (I), optionally with substituents for the hydrogen atoms shown: (H1-9), or a pharmaceutically acceptable salt of said compound where: (a) -------- represents that there are two conjugated double bonds between the atoms comprised by the dashed line; (b) X¿1? and X2 are separately selected from an oxygen atom or an NH?9¿ group, said X¿1? and X2 being bound by a single bond to the ring when attached to H?7 or H8¿ and by a double bond when not bound to H?7 or H8; (c) H1-9¿ are hydrogens with the provision that H9 is only present when at least one of X¿1? and X2 is the NH?9¿ group; (d) H?7 and H8¿ are hydrogens that are attached to different atoms selected among X¿1?, X2 and the nitrogen atom (N) in the quinoline ring, for the manufacture of a composition intended for treating inflammatory bowel disease or conditions associated with this disease. Also described are methods for treating inflammatory bowel disease or conditions associated with this disease in which methods the above compounds are administered to a living body. Particularly preferred compounds are N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or a salt thereof.</p> |
